Medindia

X

Largely Untapped COPD Population Will Drive Growth in China

Wednesday, September 19, 2007 General News J E 4
Advertisement
WALTHAM, Mass., Sept. 18 Decision Resources, one of theworld's leading research and advisory firms focusing on pharmaceutical andhealthcare issues, forecasts that the chronic obstructive pulmonary disease(COPD) population in China will experience growth, due to an expandingdiagnosed and drug-treated population. According to the new Emerging Marketsreport entitled COPD in China, the diagnosed and drug-treated populations willincrease at annual rates of 1.6 percent and 2.2 percent, respectively, overthe next five years. The greatest growth in the prevalent population will beseen in the urban setting among patients aged 60-70 years and those aged 80years and older. Additional drivers of market growth include improvements inhealth insurance and in the socioeconomic status of patients.

The report also finds that significant factors are currently constrainingthe COPD market, including a lack of disease awareness, patients' limitedaccess to care (particularly in the rural setting), the high cost of drugs,and reimbursement restrictions placed on certain agents. Additionally,inexperienced Chinese physicians who are unaware of or don't have access tospirometry (the most common of the Pulmonary Function Tests which measureslung function) confuse COPD with asthma, thus providing less optimal diseasemanagement. Chinese physicians also struggle with low compliance rates amongtheir patients, further constraining optimal drug sales.

"China's COPD market presents a potentially lucrative opportunity formultinational corporations," said Regina Cebula Jammen, analyst at DecisionResources. "By establishing effective COPD awareness programs in collaborationwith China's Global Alliance Against Chronic Respiratory Diseases,multinational corporations have the opportunity to tap into a COPD prevalentpopulation that is significantly underdiagnosed and undertreated."

About Emerging Markets -- China

Emerging Markets -- China is the first and only syndicated report seriesfocusing on high-growth emerging markets with comprehensive disease-specificanalysis. With these reports, biopharmaceutical companies can accomplish thefollowing:

Decision Resources, Inc., (www.DecisionResources.com) is a world leader inhealthcare market research publications, advisory services, and consultingdesigned to help clients shape strategy, allocate resources, and master theirchosen markets.

All company, brand, or product names contained in this document may betrademarks or registered trademarks of their respective holders.-- More accurately assess their commercial opportunity for Western brands in key pharmaceutical markets of China -- Beijing, Shanghai, Guangzhou -- and in the high-growth second-tier markets of Tianjin, Wuhan, Nanjing, Hangzhou, and Jinan. -- Understand the physician treatment patterns and drivers of choice in key first- and second-tier cities based on primary research. -- Gain a clear perspective of the Chinese 5-year market forecast at the drug level, broken out by urban and rural areas, and by sales from multinational and Chinese-based companies. About Decision Resources

SOURCE Decision Resources
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Caliper Life Sciences to Participate in America's ...
S
TEMIS to Support Bayer HealthCare's Drug Discovery...